SCHEMBL6320288

SCHEMBL6320288

O=CCNCC(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
KIF11 P52732 8/20 0.36
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KCNN4 O15554 2/20 0.33
ADH1B P00325 1/20 0.33
ADH1C P00326 1/20 0.33
ADH1A P07327 1/20 0.33
ADH7 P40394 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
XBP1 P17861 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29257171 0.77 ADH1B (0.48) MEN1KMT2AKIF11ALDH1A1SMN1; SMN2
SCHEMBL27270010 0.74 KCNN4 (0.50) MEN1KMT2AKIF11ALDH1A1SMN1; SMN2
SCHEMBL440368 0.73 KIF11 (0.41) MEN1KMT2AKIF11ALDH1A1KCNN4
SCHEMBL6367395 0.71 MEN1 (0.42) MEN1KMT2AKIF11ALDH1A1SMN1; SMN2
SCHEMBL11034545 0.70 KIF11 (0.48) KIF11ADH1BADH1CADH1AADH7
SCHEMBL6669392 0.68 KCNN4 (0.48) MEN1KMT2AKIF11ALDH1A1SMN1; SMN2
SCHEMBL7075423 0.68 KIF11 (0.44) MEN1KMT2AKIF11SMN1; SMN2KCNN4
SCHEMBL3130447 0.67 MEN1 (0.58) MEN1KMT2AADH1BADH1CADH1A
SCHEMBL4461018 0.66 KCNN4 (0.47) MEN1KMT2AKIF11ALDH1A1SMN1; SMN2
Water SCHEMBL28983963 0.66 SIGMAR1 (0.51) MEN1KMT2AKIF11ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6852731-B2 Antiviral compounds PFIZER (US) 2005-02-08 US disclosed
US-20040242884-A1 ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY 2004-12-02 US disclosed
EP-1472260-A2 THIENO(3,2-B)PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2004-11-03 EP disclosed
WO-2003059878-A2 THIENO (3, 2-B) PYRIDONES AS ANTIVIRAL COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040242884-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, IRF3, IFNAR1 MEN1 1462/4885KMT2A 2402/4885KIF11 903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.